Packaging cell lines for generation of high titers of recombinant AAV vectors
US6924128B2 · kind B2 · utility
29Cited by
45References
22Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 6, 2000 |
| Grant date | Aug 2, 2005 |
| Priority date | — |
| Expiry date | Sep 26, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14152
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
AAV vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantities of such recombinant vectors in amounts that would be clinically useful for human gene therapy application. Stable AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and can negatively affect the host cell. This invention provides packaging systems and processes for packaging AAV vectors that effectively circumvent these problems and that allow for substantially increased packaging efficiency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.